Fig. 8.

147 exerts widespread protection in multiple organs. a, b qPCR for Grp78 (a) or Cat (b) in left ventricular, liver, kidney, and brain extracts from WT mice 24 hours post treatment with control or 147 (n = 3). c Ratio of transcript levels of Xbp1s to Xbp1 as determined by qPCR in liver extracts from WT or ATF6 KO mice 24 hours post treatment with control or 147 and then treated with 2 mg/kg of TM for designated periods of time (n = 3). d Triglyceride levels in liver extracts from WT or ATF6 KO mice 24 hours post treatment with control or 147 and then treated with 2 mg/kg of TM for 12 hours  (n = 3). e Experimental design for testing the effects of 147 in the hearts of mice subjected to 30 min of myocardial infarction, and then examined 24 hours after the initiation of reperfusion. Red bars depict the bolus administration of the control compound, while blue bars depict the bolus administration of 147. f–h Relative infarct sizes in the heart (f) (n = 6–7 for each experiment, as shown), kidney (g), and brain (h) (n = 4–5 for each experiment, as shown) of male mice 24 hours after reperfusion. i–k Plasma cTnI (i) (n = 6–7 for each experiment, as shown), plasma creatinine (j), and neurological score based on the Bederson system of behavioral patterns post-cerebral ischemic injury of male mice 24 hours after reperfusion of respective injury models (n = 4–5 for each experiment, as shown). Data are represented as mean ± s.e.m. Two-group comparisons were performed using Student’s two-tailed t test, and all multiple group comparisons were performed using a one-way ANOVA with a Newman–Keuls post hoc analysis. **P ≤ 0.01, ***P ≤ 0.001; ns not significant